LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ(TM)) in South Korea for the Treatment of Presbyopia
(NASDAQ:LENZ),(TAI:1795.TW), SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for the review and approval of VIZZTM, for […]